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Aim of the study: The aim of the work
was to determine the influence of tyr-
phostin AG1296, an inhibitor of platelet-
derived growth factor receptor (PDGFR)
tyrosine kinase, on autocrine growth of
rhabdomyosarcoma (RMS) cells. 
Materials and methods: RMS cells were
cultured in serum-free DMEM/F12 medi-
um. Modified crystal violet (CV) and MTT
methods were used to determine the
RMS cells’ proliferation and viability. In-
 fluence of the investigated inhibitor on
cell apoptosis or necrosis was deter-
mined by differential staining with
Hoechst No. 33258 and propidium iodide.
Results: The AG1296 inhibitor affects
RMS cell proliferation in a dose-depen-
dent way at the concentration range 
1–100 µM. At concentrations above 
25 µM there was 100% inhibition of
growth of these cells and a cytotoxic ef-
fect was noticed. 50% inhibition of RMS
cells proliferation (IC50) was observed at
concentration 6.65 ±0.44 µM (deter-
mined by CV method) and 7.30 ±0.26 µM
(determined by MTT method). The dif-
ferential staining method shows that this
inhibitor causes a cytotoxic effect.
Conclusion: The results of these exper-
iments indicate that autocrine growth of
RMS cells is regulated by at least one 
autocrine loop, involving platelet-de-
rived growth factor (PDGF) and its re-
ceptor (PDGFR).
The fact that tyrphostin AG1296 is able
to complete inhibition of RMS cell
growth in vitro gives a chance for pro-
viding a new group of antitumor drugs,
which may be more effective than the
medicines used so far. 
Key words: tyrosine kinase, signal trans-
duction, platelet-derived growth factor
receptor, tyrphostin AG1296, RMS cells.
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Introduction
Protein tyrosine kinases (PTK) play a crucial role in the regulation of many
cellular processes [1]. Tyrosine kinases are important mediators of the signalling
cascade, determining key roles in diverse biological processes such as growth,
differentiation, metabolism and apoptosis in response to external and internal
stimuli [2]. Their activity is normally tightly controlled and regulated. Perturbation
of PTK signalling by mutations and other genetic alterations results in dereg-
ulation of kinase activity and malignant transformation [3]. Dysregulation of pro-
tein kinases occurs in a variety of diseases including cancer, diabetes, and au-
toimmune, cardiovascular, inflammatory, and nervous disorders [4]. 
Though their activity is tightly regulated in normal cells, they may acquire
transforming functions due to mutation(s), overexpression and auto -
crine/paracrine stimulation, leading to malignancy. Normally the level of cel-
lular tyrosine kinase phosphorylation is tightly controlled by the antagoniz-
ing effect of tyrosine kinases and tyrosine phosphatases. There are several
mechanisms by which tyrosine kinases might acquire transforming functions,
but the ultimate result is the constitutive activation of normally controlled path-
ways leading to the activation of other signalling proteins and secondary mes-
sengers, which serves to hamper the regulatory functions in cellular responses
such as cell division, growth and cell death. Constitutive activation of tyro-
sine kinases may occur by several mechanisms. Important mechanisms lead-
ing to tyrosine kinase deregulation are mutations, deletions and chromoso-
mal translocation [2, 5].
There exists a whole group of oncogenic tyrosine kinases activated by chro-
mosomal translocations, which are included in the fusion tyrosine kinase fam-
ily due to their structure resemblance. Fusion tyrosine kinases (FTKs) such as
BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGFβR, TEL/TRKC(L), and NPM/ALK arise
from reciprocal chromosomal translocations and cause acute and chronic
leukaemias and non-Hodgkin’s lymphoma [6]. FTKs and other oncogenic ty-
rosine kinases such as v-Src and HER-2/neu activate multiple signalling path-
ways responsible for protection from apoptosis, induction of growth factor in-
dependent proliferation, transformation, and resistance to therapeutic drugs
and to γ-radiation [6, 7].
Autocrine-paracrine stimulation serves as an important mechanism for the
constitutive activation of tyrosine kinases, especially receptor tyrosine kinas-
es. This activation loop is stimulated when a receptor tyrosine kinase is abnormally
expressed or overexpressed in the presence of its associated ligand or when
there is overexpression of the ligand in the presence of its cognate receptor. Au-
tocrine/paracrine stimulation plays a role in a variety of human cancers [2, 8]. 
Autocrine loops involving the epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR), or insulin-like growth factor
receptor (IGFR) have been described in many cancers [9-14]. Increased expression
of EGFR is reported in many human cancers including non-small cell lung can-
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cer, bladder cancer, breast cancer and glioblastoma multifor-
me [2]. PDGF and its receptor play an important role inlung
and prostate lung cancers, renal cell carcinoma, chronic mon-
omyelocytic leukaemia (CMML) and glioblastoma [2, 15]. Co-
-expression of IGFR and its ligands IGF I and IGF II was re-
ported in the pathogenesis of breast cancer, prostrate
cancer and small cell lung cancer [2].
Constitutive oncogenic activation in cancer cells can be
blocked by selective tyrosine kinase inhibitors, which is there-
fore considered a promising approach for innovative genome-
based therapeutics. Recent progress in determining the mech-
anisms by which growth factors control cell proliferation has
contributed to the development of treatment strategies that
target specific signal transduction pathways to control pro-
liferative disorders. Hence low molecular weight tyrosine phos-
phorylation inhibitors (tyrphostins) have been proposed to
be prospective anti-proliferating agents.
PDGF and its receptors are involved in a variety of diseases:
cancers, atherosclerosis, balloon injury induced restenosis,
pulmonary fibrosis and more. In all cases enhanced signalling
of the receptor is the hallmark. In some cases, such as chron-
ic monomyelocytic leukaemia (CMML), persistent PDGFR sig-
nalling is essential for the survival of the cancer cell [15]. These
findings induced the research community as well as the phar-
maceutical industry to develop agents that block PDGFR sig-
nalling (e.g. AG17, AG370, AG1295, STI571, CT52923, SU11248
and more). 
These results strongly suggest the potential role of
PDGFR inhibitors in RMS cells growth regulation and viability.
The aim of the work was to determine the influence of tyr-
phostin AG1296 (inhibitor of PDGFR tyrosine kinase) on au-
tocrine growth of rhabdomyosarcoma RMS cells. 
Materials and methods
Chemicals and reagents
Dulbecco’s modified minimal essential medium (DMEM),
Hoechst No. 33258, propidium iodide and tyrosine kinase in-
hibitor AG1296 were purchased from Sigma (St. Louis, Mo., USA).
Fetal bovine serum (FBS) was obtained from Biowest, South
American Origin. Other reagents were provided by POCh (Gli-
wice, Poland). Stock solutions of the tyrphostin were prepared
by dissolving the compounds in dimethylsulfoxide (DMSO) to
a final concentration of 10 mM and storing the resultant so-
lutions at –20°C. DMEM/F12 (1 : 1) medium was used do di-
lute stock solutions to working concentrations (0.1-100 µM).
Cell culture
RMS cells were obtained from the American Type Culture
Collection (ATCC) and cultured in DMEM, supplemented with
100 IU/ml penicillin and 100 mg/ml streptomycin in the pres-
ence of 10% fetal bovine serum (FBS). The cells were passaged
two times per week using 0.05% trypsin solution with 0.02%
EDTA in phosphate buffered saline (PBS) without Ca2+ and Mg2+.
Cell proliferation assay
Target cells were seeded on 96-well plates at concen-
trations of 8 × 103 cells/well in DMEM, supplemented with
100 IU/ml penicillin and 100 mg/ml streptomycin in the pres-
ence of 10% FBS. Following 24 h of incubation, the culture
medium was replaced with serum-free DMEM/F12 (1 : 1) sup-
plemented with transferrin (5 mg/ml), sodium selenite 
(2 ng/ml) and albumin (0.5 mg/ml) [DMEM/F12+]. After an
additional 24 h of incubation (Day 0), the medium was re-
placed with serum-free DMEM/F12+ medium containing ty-
rosine kinase inhibitor AG1296 (0.1-100 µM). The incubation
was continued for the next 48 h at 37°C in humidified at-
mosphere. The modified crystal violet (CV) staining method
[16] and the MTT tetrazolium assay (MTT) [17] were used to
determine the influence of the tyrphostin on proliferation
of target cells. The absorbance was measured using a Tecan
(Spectra Fluor Plus) multiscan plate recorder. Ten replicate
wells were used for each experiment. The influence of tyrosine
kinase inhibitors was expressed as a relative (to the controls)
decrease in cell growth determined after 48 h of incubation
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where Gi is growth inhibition, and Ao, Ac, Ai are average
values of absorbance at 540 nm (CV) or 570 nm (MTT) of the
control sample at the start of the experiment (Ao), after 48 h
of incubation (Ac), and after 48 h of incubation with the in-
vestigated inhibitors (Ai).
Assessment of cell viability
The differential staining method (Hoechst 33258/PI)
was used in the investigation of the effect of tyrphostin
AG1296 on the viability of RMS cells [18]. The cells were seed-
ed on 24-well plates at a density of 3 × 104 per well in 0.8 ml
DMEM with 10% FBS. Following 24 h of incubation, the cul-
ture medium was replaced with serum-free DMEM/F12+ medi-
um. After an additional 24 h of incubation, the cells were ex-
posed to 10-100 µM concentrations of the investigated
tyrphostin and 50 nM paclitaxel (Taxol). The experiment was
carried out for 48 h and then Hoechst No. 33258 and pro-
pidium iodide were added to the final concentration of 5 µg/ml
and 1 µg/ml, respectively. After 15 min, the cells were directly
examined on plates with a fluorescent Olympus IMT 2 mi-
croscope. Two excitation filters were used: one allowing for
excitation of both dyes, the other allowing for excitation of
only PI. The Image J software was used for image process-
ing (emerging RGB channels, enhancing contrast and sharp-
ening) and the quantitative analysis of the processed pic-
tures (cell counting). It allowed for estimating the fraction
of dead cells (PI/DNA signal), viable cells (Hoechst 33258/DNA
signal), and apoptotic cells (Hoechst 33258/DNA signal
with morphological changes characteristic of last-phase apop-
tosis). Each experiment was repeated at least six times. Im-
ages with the number of cells exceeding approximately 100
were selected for the analysis.
Statistical analysis
The statistical analysis was performed using the Statis-
tica 6 program. The effects of different tyrphostin concen-
trations on RMS cell proliferation were analysed using one
way ANOVA, followed by Dunnett’s test. The Mann Whitney
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U test was used to determine differences in the percentage
of alive, apoptotic and necrotic cells in the control sample
versus tyrphostin or paclitaxel (Taxol) treated samples. Dif-
ferences were considered significant at p < 0.05. The mean
± SEM of at least ten replicates (CV) or four replicates (dif-
ferential staining method) were used for statistical com-
parison.
Results
Rhabdomyosarcoma cells were exposed for 48 h to tyro-
sine kinase inhibitor AG1296 added at the concentration range
of 0.1-100 µM. The effect of the investigated tyrphostin de-
termined by the CV and MTT methods is shown in Fig. 1. 
The AG1296 inhibitor affects RMS cell proliferation in
a dose-dependent manner at the concentration range 
1-100 µM. Both methods showed 50% inhibition of cell growth
in the concentration range 5-10 µM. Tyrphostin AG1296
caused an effect of growth inhibition (Gi) of RMS cells. The
growth of the investigated cells was almost completely in-
hibited at concentration 25 µM. Gi reached 93.79 ±5.37% (de-
termined by the CV method) and 88.91 ± 5.17% (by MTT
method). At concentrations higher than 25 µM there was
100% inhibition of growth of these cells and a cytotoxic ef-
fect was observed.
50% inhibition of the growth of RMS cells was determined
by fitting a sigmoidal model of the dose-dependent effect
of the investigated tyrphostin (Fig. 2), calculated from the
equation:
100
H [%K] = –––––––––––––––––––––––––––––––––––––––––––
1 + 10log (IC50– Cinh) . p
IC50 coefficient calculated from the growth inhibition curves
was 7.76 ±0.35 µM for AG1296. The results showed a cyto-
static activity against RMS cells of the investigated tyrosine
kinase inhibitor.
The investigated tyrosine kinase inhibitor was also ex-
amined for its cytotoxic potential and the ability to induce
tumour cell apoptosis or necrosis. The influence of tyrphostin
AG1296 on target cell viability was assessed after double stain-
ing with Hoechst 33258 and propidium iodide. Viable cells were
dyed on blue, apoptotic on light-blue and necrotic cells on
red. The effect of 10 µM concentration of tyrphostin AG1296
in comparison with the 50 nM dose of paclitaxel is shown
in Fig. 3. 
Apoptosis is the predominant form of cell death and oc-
curs under a variety of physiological and pathological con-
ditions. Apoptotic cells were clearly distinguishable by their
characteristic morphology (cytoplasmic blebbing, cell shrink-
age, nuclear condensation and fragmentation) (Fig. 3). Such
morphological alterations were found in all investigated cell
cultures; however, in the case of control cultures, they did
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Fig. 1. Growth inhibition of cancer cell line (RMS) by inhibitor
AG1296 determined by modified crystal violet staining method
and MTT test after 48 h of incubation in serum-free medium
(DMEM/F12)
NS – non-significant (p > 0.05) in comparison with control sample (without
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Fig. 2. Dose-dependent effect of tyrphostin AG1296 on the
growth of RMS cells after 48 h of incubation in serum-free
DMEM/F12+ medium 
Data: CV + MTT
Model: logistic
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Fig. 3. Typical picture of the cultures of RMS cells after 48 h of incubation: a) control, b) 10  µM AG1296 and c) 50 nM Taxol
Dark blue – viable cells; blue (with nuclear fragmentation) – apoptotic cells; red – necrotic cells 
quantitative determination of the number of viable, apop-
totic and necrotic cells are presented in Fig. 4.
Quantitative results obtained in the study confirm the mi-
croscopic observations. The differential staining method
proved that this inhibitor caused a cytotoxic effect. The per-
centage of apoptotic cells was increased in a dose-depen-
dent manner by treatment with tyrphostin AG1296. Between
the control and different concentrations of tested inhibitor
the amount of viable cells is successively dropping (four times
at the highest concentration of tyrphostin). With increasing
concentration of AG1296, the percentage of apoptotic cells
increases (from 11.1% for the control to 75.3% for concentration
of 100 µM). The obtained results are statistically significant.
Only for 50 µM concentration of tyrphostin are the amounts
of apoptotic cells for the inhibitor and the control not sig-
nificantly different. This is probably due to the large dispersion
of obtained results. The results presented clearly indicate the
cytotoxic effect of the action of the tested PDGFR inhibitor.
Prolonging the incubation time to 72 h resulted in a dramatic
decrease of viability of cells to about 40% (results not shown).
Discussion
Rhabdomyosarcoma (RMS) is the most frequent childhood
cancer originating from skeletal muscle, and patient survival
is poor in the case of metastatic disease. New targeted ther-
apeutics are critically needed [19]. Over the past two
decades, research into the molecular mechanisms of RMS
has identified key genes and signalling pathways involved
in disease pathogenesis. Several members of the receptor
tyrosine kinase (RTK) family of cell surface receptors have been
characterized as druggable targets for RMS. Through small
molecule inhibitors, ligand-neutralizing agents, and mono-
clonal receptor-blocking antibodies, RTK activity can be
manipulated to block oncogenic properties associated with
RMS [20].
The role of tyrosine kinases in cancer molecular patho-
genesis is immense and recently kinases have come into













vogue as potential anticancer drug targets, as a result of a cou-
ple of anticancer drugs that are on the market. The complexity
and the number of tyrosine kinases have greatly increased
with the sequencing effort of the Human Genome Project,
thus providing more opportunities for drug discovery. Recent
understanding of the molecular pathophysiology of cancer
has highlighted that many tyrosine kinases are found up-
stream or downstream of epidemiologically relevant onco-
genes or tumour suppressors, in particular the receptor ty-
rosine kinases [2].
Several types of PDGF antagonists have been de-
scribed, including antibodies or DNA aptamers against lig-
ands or the extracellular part of the receptors, as well as
low molecular weight receptor kinase inhibitors (e.g. ima-
tinib, sunitinib and sorafenib) [21-27]. The latter also inhibited
the growth of RMS cells (IC50 = 5 µM) [28]. Imatinib rep-
resents a kinase inhibitor for which there is already some
clinical experience [21, 29]. Another PDGF receptor antag-
onist that, despite having a broad specificity, shows a tol-
erable toxicity profile and promising results from phase I clin-
ical trials is SU11248 [21]. The mechanism of action of
AG1296, a potent and specific inhibitor of the platelet-de-
rived growth factor (PDGF) receptor tyrosine kinase, has been
investigated [30-32].
We have determined whether blockade of PDGFR signalling
pathways inhibits autocrine growth and viability of RMS cells
in vitro. In RMS cells, AG1296 inhibited proliferation in a dose-
dependent manner with an IC50 value of 7.76 ±0.35 µM. Our
results indicate that each of the investigated tyrphostins at
concentrations > 25 µM is able to completely inhibit RMS au-
tocrine cell growth. The obtained results were very similar,
regardless of the method of growth evaluation which was
applied (CV, MTT). At concentrations higher than 40 µM, the
amount of cells dropped below the initial density, which in-
dicated the cytotoxic effect.
The differential staining method showed that the inves-
tigated tyrphostin, used at concentration > 10 µM, had di-
rect cytotoxicity on the RMS cell line. After the 48-hour in-
cubation the percentage of viable cells decreased significantly
with the increase of tyrphostin concentration and equalled
75.9% (20 µM concentration), 69.4% (40 µM concentration),
58.7% (80 µM concentration) and 22.6% (100 µM concen-
tration). It turned out that the kinase inhibitor PDGFR stim-
ulates mainly the apoptotic process of the investigated cells.
The amount of apoptotic cells increased from 18.5% for the
20 µM concentration of tyrphostin AG1296 to 75.5% for the
100 µM concentration of tyrphostin AG1296. With the in-
cubation time prolonged to 72 h there was still observed a de-
crease of the number of viable cells to 12.9% and an increase
of the amount of necrotic cells up to 25%.
The results of these experiments indicate that autocrine
growth of RMS cells is regulated by at least one autocrine
loop, involving PDGF and its receptor (PDGFR). The fact that
tyrphostin AG1296 is able to complete inhibition of RMS cell
growth in vitro gives a chance for providing a new group of
antitumor drugs, which may be more effective than the med-
icines used so far. 
Fig. 4. Effect of tyrphostin AG1296 and Taxol (as the positive con-
trol) on the induction of apoptosis in RMS cells, after 48 h 
of incubation in DMEM/F12+ medium. The average percentage 
of viable cells, apoptotic cells and necrotic cells 
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